MAPT and frontotemporal dementia: There has been relatively less progress in disease-modifying therapy for non-Alzheimer pathologies in the frontotemporal dementia spectrum, but this is an increasingly active area of research, with a number of candidate agents in early stage trials targeting sporadic tau and TDP-43 pathologies as well as the pathogenic pathways of GRN and C9orf72 mutations [214].